Protara Therapeutics, Inc. announced the appointment of Jathin Bandari, M.D., as Chief Medical Officer. Dr. Bandari is a practicing urologic oncologist, recently serving at the University of Rochester where he specialized in both minimally invasive urologic oncology and advanced open pelvic retroperitoneal cancer surgery, and where he maintains a faculty appointment. Dr. Bandari joined Protara in April 2020 as Vice President, Head of Clinical Development, and most recently was Interim Chief Medical Officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.79 USD | -0.36% | -4.78% | +48.79% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+48.79% | 57.45M | |
+9.83% | 115B | |
+10.80% | 105B | |
-10.84% | 22.71B | |
-1.43% | 21.83B | |
-10.56% | 18.18B | |
-41.92% | 16.52B | |
-15.11% | 16.01B | |
+6.62% | 14.14B | |
+17.53% | 10.71B |
- Stock Market
- Equities
- TARA Stock
- News Protara Therapeutics, Inc.
- Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer